Cetera Investment Advisers trimmed its position in Incyte Corporation (NASDAQ: INCY) by 18.7% in the

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing R

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65

Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemoth

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Fre

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the com

Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed

Incyte NASDAQ: INCY reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a y

Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-wee

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estim

Drugmaker Incyte Corp reported on Tuesday higher second-quarter earnings and raised its annual reven

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyss

ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Second Quarter 2026 Financial Results an

Entropy Technologies LP increased its position in Incyte Corporation (NASDAQ: INCY) by 29.6% in the

Dai ichi Life Insurance Company Ltd boosted its holdings in Incyte Corporation (NASDAQ: INCY) by 60.

INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueli

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth I

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patie

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump

The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record

Large-cap stocks worst performers last week, including BEKE, RDDT, FUTU, JHX, INCY, NUE, BAH, XPEV,

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings